(Q33204393)

23 July 2017

1 reference

title

Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis (English)

1 reference

23 July 2017

0 references

Richard A Rudick

1

1 reference

23 July 2017

publication date

1 July 2004

1 reference

23 July 2017

published in

Journal of Neuroimaging

1 reference

23 July 2017

volume

14

1 reference

23 July 2017

issue

3 Suppl

1 reference

23 July 2017

page(s)

54S-64S

1 reference

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

23 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1552-6569.2004.TB00279.X

A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1552-6569.2004.TB00279.X

Eight-year follow-up study of brain atrophy in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1552-6569.2004.TB00279.X

Interferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1552-6569.2004.TB00279.X

Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1552-6569.2004.TB00279.X

Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1552-6569.2004.TB00279.X

Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1552-6569.2004.TB00279.X

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1552-6569.2004.TB00279.X

Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1552-6569.2004.TB00279.X

Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1552-6569.2004.TB00279.X

Whole brain volume changes in patients with progressive MS treated with cladribine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1552-6569.2004.TB00279.X

Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1552-6569.2004.TB00279.X

Optimizing the association between disability and biological markers in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1552-6569.2004.TB00279.X

Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1552-6569.2004.TB00279.X

10.1111/J.1552-6569.2004.TB00279.X

21 January 2018

Identifiers

DOI

1 reference

23 July 2017

1 reference